Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Digestive System Cancer
Explore 73 assets in Digestive System Cancer →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Copper Cu 64 Anti-Cea Monoclonal Antibody M5A (this asset) | City of Hope Medical Center | N/A | D · 30 |
| Irinotecan | Amgen | P2 | BB |
| Dexasone | Cedars-Sinai Medical Center | P4 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P2 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Brian Anderson, MD | P4 | BB |
| Epinephrine | Cedars-Sinai Medical Center | P4 | BB |
| Mlf 541 | B. Braun Melsungen AG | P3 | BB |
| Marcaine | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | P4 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | B |
+42 more in the Digestive System Cancer cohort
Other indications for Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | Early P1 | C · 39 |
| Rectal Carcinoma | — | Early P1 | C · 39 |
| Extrahepatic Bile Duct Carcinoma | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Copper Cu 64 Anti-Cea Monoclonal Antibody M5A in Digestive System Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/copper-cu-64-anti-cea-monoclonal-antibody-m5a-digestive-system-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →